Navigation Links
Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
Date:11/2/2011

WALTHAM, Mass., Nov. 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that pharmacodynamic analysis in a subset of patients from ENCORE 301, a randomized phase 2 study of exemestane with and without entinostat in advanced breast cancer patients, will be presented in an oral session at the American Association for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics Conference.  

The positive data was from ENCORE 301 (ENtinostat Combinations Overcoming REsistance), a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer, progressing on treatment with the non-steroidal aromatase inhibitors anastrozole or letrozole.  The study which met the primary endpoint of progression free survival (PFS) was presented at the ASCO Breast Cancer Symposium in September earlier this year.  

The pharmacodynamic data will be presented by Peter Ordentlich, Ph.D. in an oral session called the Proffered Paper Session 1 on Sunday, November 13, 2011 from 4:30 to 6:00 PM PT.

For media

The data will be discussed during a press conference on Sunday, November 13, 2011 at 7:30 AM PT in room 2004 of the Moscone Convention Center.  To dial in to the webcast please dial Toll-Free (US & Canada) (888) 647-7462 or International Dial-In (Toll): (201) 604-0169.

Breast Cancer and Hormone Therapy

Annually about 207,000 women have breast cancer in the United States and about 20,000 of them have metastatic breast cancer (MBC).  Approxima
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
2. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
4. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences
7. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
8. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
9. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
10. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
11. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Pharmaceuticals, Inc. (Nasdaq: ALSE ), announced today that ... Altropane Parkinson,s or Essential Tremor (POET-2) Phase III ... the program was to acquire the set of Altropane images ... Phase III registration portion of the program. The Altropane ...
... Care approach designed to help improve medication adherence to ... 3 /PRNewswire/ -- A study ... ) found that nearly half of patients hospitalized for ... therapies, significantly increasing their risk for subsequent hospitalization within ...
Cached Medicine Technology:Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 2Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 3Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 4Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 5CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 2CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 3CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 4
(Date:7/11/2014)... (PRWEB) July 11, 2014 Volunteers from ... against drug abuse this week with drug education lectures, ... education booklet distribution in cities around the world. , ... U.S. National Institute on Drug Abuse, abuse of alcohol ... annually in crime, lost work, decreased productivity and healthcare. ...
(Date:7/11/2014)... Well Intervention Market report defines and segments the well intervention ... well intervention services market in Europe is estimated to grow ... 2018, at a CAGR of 7% from 2013 to 2018. ... Market report, to get an idea of the in-depth analysis ... the Europe well intervention market, and is supported by various ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- In people with ... are similar to that seen in drug addicts as ... are clear differences in brain activity between patients who ... mirror those of drug addicts," study author Dr. Valerie ... in a university news release. Voon,s research involved ...
(Date:7/11/2014)... 2014 The report “Probiotics Market ... Animal Feed), Applications (Regular, Therapeutic, Preventive Health Care) ... & Forecasts to 2019 ” defines and segments ... forecasting of the market value of probiotic products ... and restraining factors for the global market with ...
(Date:7/11/2014)... are widely applied in turf and ornamentals. They enhance ... turf and ornamentals in absorption of water, nutrient uptake, ... appear healthy and strong as a result of using ... few years. The most dominating region in biostimulants markets ... share in 2013, and is estimated to grow at ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... , PHILADELPHIA, Dec. 2 Independence ... with Lincoln Financial Group. IBC will be the primary provider ... retirees, and their dependents across the nation. The Lincoln plan ... plans. , "I know I speak for all of us ...
... who have a prostate-specific antigen (PSA) value of less ... external beam radiation therapy (EBRT) are less likely to ... a study in the December 1 issue of the ... the American Society for Radiation Oncology (ASTRO). PSA levels ...
... ... microwave signal transmissions away from users will be available in early 2010 from Aerius ... ... transmissions away from users will be available in early 2010 from Aerius International Ltd. ...
... , ATLANTA, Dec. 2 In response ... FamilyLife, a non-profit ministry dedicated to supporting marriages and families, ... at a significant discount to military couples in Atlanta from ... Buckhead (3300 Peachtree Road NE). Weekend to Remember ...
... /PRNewswire/ -- The Universities of Sassari and Cagliari ... from the United States, announced today the results of a ... amounts of CLA (Conjugated Linoleic Acid), an Omega-6 polyunsaturated fatty ... bioactive properties for humans. , The study, conducted ...
... when women at high-risk of breast cancer are well-informed about ... prevention, only 6 percent said they were likely to take ... Center created a decision aid designed to inform women about ... was first used to stop breast cancer from returning and ...
Cached Medicine News:Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:New Study Confirms Health Benefits of Pecorino Romano Cheese 2Health News:New Study Confirms Health Benefits of Pecorino Romano Cheese 3Health News:High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: